HealthQuill China
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, has given a four-point rebuttal to the US government’s accusations against the global health agency after the nation withdrew from being a member.
Drugs Health Medical

WHO director-general rebuts US criticism, plans to cut budget

Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, has given a four-point rebuttal to the US government’s accusations against the global.

Read More
China’s YolTech Therapeutics, a biotechnology startup, has started its clinical trial of an investigational therapy for treating transfusion-dependent beta-thalassemia (TDT), a severe genetic blood disorder.
Drugs Health Medical

China’s YolTech starts gene editing trial for treating a blood disorder 

China’s YolTech Therapeutics, a biotechnology startup, has started its clinical trial of an investigational therapy for treating transfusion-dependent beta-thalassemia (TDT), a severe genetic.

Read More
The US, the world’s second-largest greenhouse gas emitter in the world, will withdraw from a global pact to limit global warming.
Climate Health Medical

US to pull out from Paris Agreement that limits global warming 

The US, the world’s second-largest greenhouse gas emitter in the world, will withdraw from a global pact to limit global warming.

Read More
The US, the World Health Organization’s top donor, has decided to withdraw from the global health body, accusing it of “mishandling” the Covid-19 pandemic.
Health Medical Pharma

US to withdraw from WHO after an executive order from Donald Trump

The US, the World Health Organization’s top donor, has decided to withdraw from the global health body, accusing it of “mishandling” the Covid-19.

Read More
US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which is under trial, for treating chronic kidney diseases.
Drugs Health Pharma

Vertex, China’s Zai to develop, commercialise kidney disease drug

US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which.

Read More
China has approved Merck & Co.’s human papillomavirus vaccine for males between nine and 26 years amid a fall in sales for the jab among women in the world’s most populous country, according to a company statement.
Drugs Health Medical

China approves Merck’s human papillomavirus jab for use in males 

China has approved Merck & Co.’s human papillomavirus vaccine for males between nine and 26 years amid a fall in sales for the.

Read More
China will develop humanoid robots for elderly care and support scientific and technological projects related to senior citizens, according to a state-run news agency.
Health Medical Pharma

China to make humanoid robots, brain-computer interfaces for elderly

China will develop humanoid robots for elderly care and support scientific and technological projects related to senior citizens, according to a state-run news.

Read More
A rise in cases of respiratory infections in China is within the expected range during this time of the year, and the World Health Organization has not observed “unusual outbreak patterns.”
Drugs Health Medical

Respiratory infections in China have no ‘unusual outbreak patterns’

A rise in cases of respiratory infections in China is within the expected range during this time of the year, and the World.

Read More
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight cancer for an upfront payment of $925 million.
Drugs Medical Pharma

WuXi Biologics sells global rights to cancer antibody to Candid for $925m

China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight.

Read More